Evidence map›Paper›PMID 21463514›Full record

ArticleBreast cancer research : BCR2011

miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention.

Niloo Srivastava, Siddharth Manvati, Archita Srivastava, Ranjana Pal, Ponnusamy Kalaiarasan, Shilpi Chattopadhyay, Sailesh Gochhait, Raina Dua, Rameshwar N K Bamezai

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 82 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Iranian journal of biotechnology · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. MicroRNAs: Crucial Regulators of Stress.MicroRNA (Shariqah, United Arab Emirates) · 2020
    Review
  12. Article
  13. Article
  14. Low-level serum miR-24-2 is associated with the progression of colorectal cancer.Cancer biomarkers : section A of Disease markers · 2018
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1.Journal of experimental & clinical cancer research : CR · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Niloo SrivastavaNational Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, New Mehrauli Road, Saraswatipuram, New Delhi 110 067, India.
Siddharth Manvati
Archita Srivastava
Ranjana Pal
Ponnusamy Kalaiarasan
Shilpi Chattopadhyay
Sailesh Gochhait
Raina Dua
Rameshwar N K Bamezai
Jawaharlal Nehru University · INShri Mata Vaishno Devi University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNew levels of gene regulation with microRNA (miR) and gene copy number alterations (CNAs) have been identified as playing a role in various cancers. We have previously reported that sporadic breast cancer tissues exhibit significant alteration in H2AX gene copy number. However, how CNA affects gene expression and what is the role of miR, miR-24-2, known to regulate H2AX expression, in the background of the change in copy number, are not known. Further, many miRs, including miR-24-2, are implicated as playing a role in cell proliferation and apoptosis, but their specific target genes and the pathways contributing to them remain unexplored.

methodsChanges in gene copy number and mRNA/miR expression were estimated using real-time polymerase chain reaction assays in two mammalian cell lines, MCF-7 and HeLa, and in a set of sporadic breast cancer tissues. In silico analysis was performed to find the putative target for miR-24-2. MCF-7 cells were transfected with precursor miR-24-2 oligonucleotides, and the gene expression levels of BRCA1, BRCA2, ATM, MDM2, TP53, CHEK2, CYT-C, BCL-2, H2AFX and P21 were examined using TaqMan gene expression assays. Apoptosis was measured by flow cytometric detection using annexin V dye. A luciferase assay was performed to confirm BCL-2 as a valid cellular target of miR-24-2.

resultsIt was observed that H2AX gene expression was negatively correlated with miR-24-2 expression and not in accordance with the gene copy number status, both in cell lines and in sporadic breast tumor tissues. Further, the cells overexpressing miR-24-2 were observed to be hypersensitive to DNA damaging drugs, undergoing apoptotic cell death, suggesting the potentiating effect of mir-24-2-mediated apoptotic induction in human cancer cell lines treated with anticancer drugs. BCL-2 was identified as a novel cellular target of miR-24-2.

conclusionsmir-24-2 is capable of inducing apoptosis by modulating different apoptotic pathways and targeting BCL-2, an antiapoptotic gene. The study suggests that miR-24-2 is more effective in controlling H2AX gene expression, regardless of the change in gene copy number. Further, the study indicates that combination therapy with miR-24-2 along with an anticancer drug such as cisplatin could provide a new avenue in cancer therapy for patients with tumors otherwise resistant to drugs.

Indexed as

ApoptosisGenes, bcl-2Antineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationCisplatinDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticHeLa CellsHistonesHumansMicroRNAsMolecular Targeted TherapyProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsCisplatinH2AX protein, humanHistonesMicroRNAsMIRN24 microRNA, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID21463514
PMCPMC3219202
OpenAlexW2152478751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.